Lord Bowness Portrait

Lord Bowness

Crossbench - Life peer

Joined House of Lords: 17th January 1996


[email protected]
Secondary Legislation Scrutiny Committee
12th Jun 2014 - 27th Apr 2017
EU Energy and Environment Sub-Committee
12th Jun 2015 - 12th May 2016
European Union Committee
8th Dec 2003 - 14th May 2014
EU Sub Committee E - Justice, Institutions and Consumer Protection
17th May 2012 - 21st May 2013
Human Rights (Joint Committee)
15th Dec 2008 - 1st May 2012
Intergovernmental Organisations Committee
15th Nov 2007 - 4th Feb 2008
Human Rights (Joint Committee)
2nd Dec 2002 - 8th Nov 2006
Committee on Chinook ZD 576
2nd Jul 2001 - 7th Nov 2002

Lords Debates - Bills Introduced - Written Questions

Commons Page Hansard Page Lord Bowness (MP)

Division Voting information

During the current Parliament, Lord Bowness has voted in 0 divisions, and never against the majority of their Party.
View All Lord Bowness Division Votes

Debates during the 2024 Parliament

Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.

Sparring Partners
View All Sparring Partners
Department Debates
View All Department Debates
Legislation Debates
Lord Bowness has not made any spoken contributions to legislative debate
View all Lord Bowness's debates

Lords initiatives

These initiatives were driven by Lord Bowness, and are more likely to reflect personal policy preferences.

Lord Bowness has not introduced any legislation before Parliament

Lord Bowness has not co-sponsored any Bills in the current parliamentary sitting

Latest 2 Written Questions

(View all written questions)
Written Questions can be tabled by MPs and Lords to request specific information information on the work, policy and activities of a Government Department
2 Department of Health and Social Care Questions
 (View all Lord Bowness's DHSC questions)
14th Sep 2026
Fampridine
To ask His Majesty's Government whether funding is in place to meet the cost of ongoing treatment with Fampridine for patients with multiple sclerosis in England; and, if not, when will it be.

NHS England published a clinical commissioning policy in July 2026 recommending prolonged-release fampridine as a routine commissioning treatment option for adults in England with multiple sclerosis (MS) and associated walking impairment who meet the defined eligibility criteria: those who score 4 to 7 on the Expanded Disability Status Scale.

Funding for prolonged-release fampridine is now available in England. NHS England began routinely commissioning the treatment from 16 July 2026 for eligible adults with multiple sclerosis and associated walking impairment who meet the policy criteria.

Baroness Merron
Parliamentary Under-Secretary (Department of Health and Social Care)
14th Sep 2026
Fampridine
To ask His Majesty's Government what are the eligibility criteria for a patient with multiple sclerosis to be prescribed Fampridine for a trial period; and what plans they have to fund ongoing treatment on terms similar to those in Wales, Scotland and Northern Ireland where such a trial shows an improvement in the patient’s mobility.

NHS England published a clinical commissioning policy in July 2026 recommending prolonged-release fampridine as a routine commissioning treatment option for adults in England with multiple sclerosis (MS) and associated walking impairment who meet the defined eligibility criteria: those who score 4 to 7 on the Expanded Disability Status Scale.

Funding for prolonged-release fampridine is now available in England. NHS England began routinely commissioning the treatment from 16 July 2026 for eligible adults with multiple sclerosis and associated walking impairment who meet the policy criteria.

Baroness Merron
Parliamentary Under-Secretary (Department of Health and Social Care)